CLLS News and Press, Cellectis S.A.

2026-02-13 14:01:58 ET More on pharmaceuticals, biotech Big Pharma's Earnings Week: Strong Performance, Obesity Wars, LOE Management And More BBH: Mature Biotech Exposure, But Limited Growth Ahead XPH: Healthcare Dashboard For January Most and least shorted m...

NEW YORK, Jan. 08, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today outlined its strategic priorities an...

2025-12-18 08:52:35 ET Topline Summary and Update Read the full article on Seeking Alpha For further details see: Cellectis: Showcasing Encouraging Data, But Still Early To Make A Run Like This

2025-12-16 10:19:17 ET Stock futures didn't move much on Tuesday as traders weighed a fresh batch of delayed economic reports. Market sentiment remains unchanged, with many still betting on at least one Federal Reserve rate cut next year.... Read the full article on Seeking Alpha ...

Arbitration Ruling Reaffirms Allogene’s Full Control of Cemacabtagene Ansegedleucel (Cema-Cel) Decision Reconfirms Allogene’s Expanded Sub-License Covering EU and UK Rights with Options for Japan and China, Clearing the Path for Allogene to Acquire Full Global Rights ...

NEW YORK, Dec. 15, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announces that the Arbitral Tribuna...

2025-12-11 21:31:37 ET ... Read the full article on Seeking Alpha For further details see: Cellectis' Allogeneic CAR-T Potential Still Justifies A 'Buy'

Eti-cel showed an 88% ORR and 63% CR (n=8) at current dose level in r/r NHL after ≥2 prior lines of therapy In vivo data suggest IL-2 may further enhance response rates and optimize eti-cel expansion and persistence IL-2 cohort enrollment to start in Q1 2026; full Phase 1 d...

NEW YORK, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today publishes an article in Natur...

2025-11-13 10:00:00 ET Read the full article on Seeking Alpha For further details see: Here are the major earnings after the close Thursday